JAMA Neurology is a leading peer-reviewed journal published by the American Medical Association, focused on advancing the understanding and treatment of neurological disorders. With an impressive impact factor and ranked in the 99th percentile among clinical neurology journals, this publication is recognized as Q1 in its category for 2023, highlighting its significance in the field. Since its inception, the journal has provided a platform for high-quality research, clinical trials, and reviews that inform both clinicians and researchers. Operating from its headquarters in Chicago, Illinois, JAMA Neurology offers rich insights into the latest advancements in neurology, featuring articles that span a wide range of topics including neurodegenerative diseases, stroke, epilepsy, and neurocritical care. Researchers and professionals are encouraged to access the journal’s content freely, as it employs open access options to promote the dissemination of critical knowledge. As a critical resource in the field of neurology, JAMA Neurology is essential for anyone involved in this dynamic and rapidly evolving specialty.

CURRENT OPINION IN CARDIOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is an esteemed journal in the field of cardiology that has been serving the academic community since 1988. With a robust focus on the latest developments and emerging trends in cardiovascular medicine, this journal aims to bridge the gap between clinical practice and research, offering critical insights and expert commentary. The journal is recognized in the medical community, achieving a 2023 Scopus rank of #148 out of 387 in its category, placing it in the 61st percentile. Although it operates under a subscription-based model, CURRENT OPINION IN CARDIOLOGY remains an essential resource for researchers, practitioners, and students seeking cutting-edge knowledge and advancements in cardiology. As a Q2 journal in the field, it continues to foster dialogue and provide a platform for disseminating impactful cardiovascular research, ultimately contributing to improved patient outcomes and informed clinical decisions.

European Journal of Paediatric Neurology, published by Elsevier Science Ltd, is a premier academic journal dedicated to advancing the field of paediatric neurology. With its ISSN 1090-3798 and E-ISSN 1532-2130, this journal serves as a vital resource for researchers, clinicians, and students alike, focusing on the latest findings and innovative treatments in paediatric neurological disorders. The journal has established itself as a leading publication in its field, achieving a Q1 classification in Pediatrics, Perinatology and Child Health, and holding a reputable Q2 status in Clinical Neurology as of 2023. Positioned within the top 88th percentile in Pediatrics and the 76th percentile in Clinical Neurology according to Scopus ranks, it publishes rigorous peer-reviewed articles that contribute significantly to clinical practice and research. Although not open access, the journal provides vital insights into the complexities of neurological conditions affecting the pediatric population, making it an essential tool for scholars and professionals striving to improve child health outcomes. With a publication trajectory spanning from 1997 to 2024, it continues to be at the forefront of paediatric neurological research, inspiring innovation and collaboration in the scientific community.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.

REVISTA DE NEUROLOGIA is a distinguished academic journal focusing on the broad fields of neurology and medicine, published in Spain since its inception in 1959. The journal plays a vital role in disseminating significant research findings, clinical studies, and advancements in neurological science, catering to an audience of researchers, clinicians, and students alike. With an ISSN of 0210-0010 and an E-ISSN of 1576-6578, this quarterly publication has maintained its commitment to enhancing the understanding of neurological disorders and therapies through rigorous peer-reviewed articles. While currently not classified as open access, it is indexed in Scopus, holding a rank of #253 out of 400 in the category of Medicine (Neurology), reflecting its relevance in the field with a 36th percentile. The journal is positioned within the Q3 quartile for both Medicine (miscellaneous) and Clinical Neurology categories as of 2023. Based in Barcelona, Spain, it is a vital resource for anyone devoted to the advancement of knowledge and practice in neurology.

Kidney360 (ISSN: 2641-7650) is a prominent open-access journal published by the American Society of Nephrology, dedicated to advancing the field of nephrology and its intersecting medical disciplines. Established with a vision to foster innovative research and promote a deeper understanding of kidney health, this journal is positioned as a vital resource for nephrologists, researchers, and healthcare professionals. With its classification in Q1 in Nephrology and Q2 in Medicine (miscellaneous) for 2023, Kidney360 ranks favorably, highlighting its commitment to publish high-quality, impactful research, recognized in the top percentile of its field. The journal's accessible platform aims to disseminate knowledge effectively, making it an essential repository for cutting-edge studies, reviews, and clinical research. By encouraging collaboration across various disciplines, Kidney360 plays a critical role in shaping the future of nephrology and enhancing patient care on a global scale.

Urologic Oncology - Seminars and Original Investigations is a premier journal published by Elsevier Science Inc, dedicated to advancing the field of urologic oncology through high-quality, peer-reviewed research and insightful scholarly discussions. With an ISSN of 1078-1439 and an E-ISSN of 1873-2496, this journal has established itself as a vital resource for professionals, researchers, and students alike since its inception in 1995. Currently holding a Q2 ranking in Oncology and a prestigious Q1 in Urology for 2023, it ranks 28th out of 120 in Urology and 177th out of 404 in Oncology within Scopus, underscoring its relevance and impact in these critical fields. While the journal operates under a subscription model, it continues to deliver compelling and transformative research aimed at enhancing patient outcomes in urologic oncology. With a focus on innovative therapies, diagnostic advancements, and clinical trials, the journal contributes significantly to ongoing dialogue and development in urologic health care.

EPILEPSY & BEHAVIOR is a premier journal dedicated to advancing the field of neurology and behavioral neuroscience, published by Academic Press Inc. Elsevier Science. With a focus on the complex interplay between epilepsy and behavioral disorders, this journal serves as a pivotal platform for researchers, clinicians, and educators alike. The journal holds a commendable position with a Q2 ranking in key categories such as Behavioral Neuroscience and Clinical Neurology, highlighting its influence and contributions to the scientific community. Notably, EPILEPSY & BEHAVIOR is indexed in Scopus, ranking in the top percentiles across various related fields, which underscores the quality and relevance of the research it publishes. As it navigates from its inception in 2000 to its ongoing work into 2024, the journal remains committed to disseminating high-quality research and insights that address critical issues in epilepsy and associated behavioral challenges, providing invaluable resources for ongoing education and innovation in the field.

NEUROPEDIATRICS is a prominent academic journal published by GEORG THIEME VERLAG KG, dedicated to advancing the understanding and treatment of neurological disorders in children. Established in 1980, this journal has consistently provided a platform for innovative research and clinical practice in the fields of pediatrics and neurology, culminating in its recognition across various rankings; it holds a Q2 rating in Pediatrics, Perinatology and Child Health, and Q3 in both Medicine (miscellaneous) and Neurology (clinical) as of 2023. While NEUROPEDIATRICS is not an open access journal, it remains a crucial resource for researchers, clinicians, and students who seek cutting-edge insights and evidence-based practices in the management of pediatric neurological issues. As a result, NEUROPEDIATRICS plays an indispensable role in shaping future research directions and improving health outcomes in this vital field.